Loading…
Loading…
EQUITY / NASDAQ · XNCM
Lantern Pharma Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.87 USD · 1.151%
Observed: Oct 2, 2026, 11:55 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 0.8601 USD · Volume 433,642
251 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -3,508,090 USD | -4,651,900 USD | — |
| Net income | -7,072,124 USD | -4,331,015 USD | — |
| Cash and cash equivalents | 6,660,170 USD | — | — |
| Total liabilities | 11,819,601 USD | — | — |
| Total equity | -3,217,252 USD | 12,522,405 USD | -125.69% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 6,660,170 USD | — | — | 4,422,838 USD | 4,422,838 USD | 8,389,486 USD | — | — |
| Net incomeIncome statement | -7,072,124 USD | -10,401,295 USD | -3,329,171 USD | — | -17,119,438 USD | -4,177,423 USD | -13,045,221 USD | -4,331,015 USD |
| Operating profitIncome statement | -3,508,090 USD | -6,913,337 USD | — | — | -17,978,494 USD | -4,349,800 USD | -13,775,732 USD | -4,651,900 USD |
| Total assetsBalance sheet | 8,602,349 USD | — | — | 11,035,811 USD | 11,035,811 USD | 13,626,810 USD | — | — |
| Total equityBalance sheet | -3,217,252 USD | — | 3,445,701 USD | 6,534,224 USD | 6,534,224 USD | 9,586,838 USD | — | 12,522,405 USD |
| Total liabilitiesBalance sheet | 11,819,601 USD | — | — | 4,501,587 USD | 4,501,587 USD | 4,039,972 USD | — | — |
| Financing cash flowCash flow statement | — | 3,991,701 USD | — | — | 1,498,240 USD | — | 971,781 USD | — |
| Investing cash flowCash flow statement | — | 4,942,250 USD | — | — | 11,057,073 USD | — | 12,761,027 USD | — |
| Operating cash flowCash flow statement | — | -6,713,540 USD | — | — | -15,676,980 USD | — | -12,884,867 USD | — |
| Capital expendituresCash flow statement | — | — | — | — | 1,715 USD | — | 1,714 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/30/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.